PremiumCompany AnnouncementsShell Advances Regulated Share Buy-Back Programme With New Repurchases23h ago
PremiumTipRanks NewswireNuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset24h agoAZNNVS
Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
PremiumRatingsBuy Rating Reiterated on Novartis as Diversified Pipeline Supports Medium-Term Growth; CHF 150 Price Target Unchanged2d agoNVS
Buy Rating Reiterated on Novartis as Diversified Pipeline Supports Medium-Term Growth; CHF 150 Price Target Unchanged
PremiumCompany AnnouncementsShell Continues Share Buy‑Back Programme With Dual‑Market Cancellations2d ago